Souhaitez-vous accéder aux communiqués récents ?

NON-REGULATORY PRESS RELEASE Oslo, October 25, 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, today announces that...

UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, met the study protocol’s predefined threshold for statistical significance and demonstrated a...

   UV1, in combination with the checkpoint inhibitors ipilimumab and nivolumab from Bristol-Myers Squibb, demonstrated a clinically meaningful overall survival benefit with no added toxicities,...

No confirmed patient deaths occurred in cohort 1 between the 3-year and 4-year follow-up. Oslo, October 12, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage...

  The orphan drug designation was granted based on data from the randomized Phase II clinical trial NIPU The results from the NIPU study will be presented at the ESMO Congress being held October...

The results from the NIPU study will be presented by the Principal Investigator as an oral presentation at the ESMO Congress 2023 in Madrid, Spain, 20-24 October 2023. Oslo, September 27, 2023 –...

Oslo, 22 August 2023: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces its second quarter 2023 results today. “In...

Oslo, 16 August 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its second...

The randomized, investigator-initiated FOCUS trial has completed enrollment of 75 patients with recurrent or metastatic head and neck squamous cell carcinoma The study will provide randomized data...

  Results from the UV1-103 trial published in Clinical Cancer Research highlight the promising efficacy and safety of UV1 and pembrolizumab in malignant melanoma Biomarker analyses demonstrate...